A phase II study of Adriamycin in previously untreated squamous cell carcinoma of the head and neck

Cancer. 1985 Dec 1;56(11):2573-5. doi: 10.1002/1097-0142(19851201)56:11<2573::aid-cncr2820561106>3.0.co;2-u.

Abstract

Twenty patients with squamous cell carcinoma of the head and neck (SCC H/N) were treated with Adriamycin (doxorubicin) at a dosage of 60 mg/m2 at 3-week intervals. No patient had received surgery, radiation, or chemotherapy before treatment with Adriamycin. Responses were observed in 44% of 18 evaluable tumors. We conclude that Adriamycin is a highly active drug in SCC H/N when no prior treatment has been administered.

MeSH terms

  • Carcinoma, Squamous Cell / drug therapy*
  • Doxorubicin / therapeutic use*
  • Drug Evaluation
  • Head and Neck Neoplasms / drug therapy*
  • Humans
  • Neoplasm Staging

Substances

  • Doxorubicin